TWC
PRQR icon

TD Waterhouse Canada’s ProQR Therapeutics PRQR Stock Holding History

TD Waterhouse Canada’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70 Hold
40
– – ﹤0.01% 2333
2026
Q1 		$68 Hold
40
– – ﹤0.01% 2242
2025
Q4 		$80 Hold
40
– – ﹤0.01% 1980
2025
Q3 		$86 Hold
40
– – ﹤0.01% 2001
2025
Q2 		$80 Hold
40
– – ﹤0.01% 1918
2025
Q1 		$52 Hold
40
– – ﹤0.01% 1889
2024
Q4 		$106 Hold
40
– – ﹤0.01% 1882
2024
Q3 		$70 Buy
+40
New +$75 ﹤0.01% 1830

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

TD Waterhouse Canada's PRQR Position: Q2 2026 in Review

TD Waterhouse Canada held its ProQR Therapeutics (PRQR) position steady in Q2 2026 at 40 shares worth $70. The position accounts for ﹤0.01% of the portfolio, ranked #2333.

TD Waterhouse Canada first reported a position in PRQR in Q3 2024 and has held it in 8 quarters since. The position peaked at $106 in Q4 2024. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

  • TD Waterhouse Canada held 40 shares of ProQR Therapeutics worth $70 as of Q2 2026.
  • TD Waterhouse Canada left its ProQR Therapeutics share count unchanged in Q2 2026.
  • ProQR Therapeutics made up ﹤0.01% of TD Waterhouse Canada's portfolio in Q2 2026, its #2333 holding.
  • TD Waterhouse Canada first reported a position in ProQR Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • TD Waterhouse Canada's ProQR Therapeutics position peaked at $106 in Q4 2024.
  • 70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on TD Waterhouse Canada's 13F filing for Q2 2026, filed 27 Jul 2026.